A 2018 report estimates that mental health issues could cost the global economy $16 trillion between now and 2030. Psychedelic drugs are needed to mitigate those costs.
Entheon Biomedical
Company Brief
Entheon Biomedical seeks to research, develop, patent, and distribute psilocybin and DMT based medicines and treatments for those suffering from substance-abuse disorders.This under-serviced market was valued at US$ 13.22 Billion in 2016, and is expected to grow to US$ 27.91 Billion by 2025.
Highlights
Related Articles
MagicMed Industries Files First Psychedelic Derivative Patent
MagicMed files with the USPTO with respect to its "broad portfolio of novel psilocybin molecular derivatives, the Psybrary™".
TSI EDITOR |
2020-07-10
Pharmadrug Inc. Provides Update on Debt Restructuring
PharmaDrug is restructuring approximately $1 million in debt in the form of convertible debentures.
TSI EDITOR |
2020-07-09
ATAI Life Sciences acquiring Kures to develop novel therapeutics for opioid abuse
Atai Life Sciences is bolstering its R&D platform with the acquisition of New York-based Kures.
TSI EDITOR |
2020-07-09
Legalizing Medicinal Use of Psilocybin on Oregon’s November Ballot
Oregon could become the first U.S. state to LEGALIZE the (medicinal) use of a psychedelic drug.
TSI EDITOR |
2020-07-09
Psychedelics Investing 101: Past and Current Psychedelic Drug Clinical Studies
Psychedelic drug R&D is ramping up rapidly. The number of past and current clinical studies on these substances will surprise you.
TSI EDITOR |
2020-07-09
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now